drugset / Trial / NCT05893576

A Relative Bioavailability Study of HRS9531 in Healthy Subjects

NCT05893576

Phase 1 Completed 50 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the relative bioavailability of the new formulation of HRS9531 injection between the original formulation of HRS9531 injection.

Timeline

Start
2023-05-15
Primary completion
2023-09-04
Completion
2023-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown